![Treatment costs for advanced prostate cancer using luteinizing hormone-releasing hormone agonists: a solid biodegradable leuprorelin implant versus other formulations | Journal of Comparative Effectiveness Research Treatment costs for advanced prostate cancer using luteinizing hormone-releasing hormone agonists: a solid biodegradable leuprorelin implant versus other formulations | Journal of Comparative Effectiveness Research](https://www.futuremedicine.com/cms/10.2217/cer.14.82/asset/images/medium/figure2.gif)
Treatment costs for advanced prostate cancer using luteinizing hormone-releasing hormone agonists: a solid biodegradable leuprorelin implant versus other formulations | Journal of Comparative Effectiveness Research
![Enzalutamide Antitumour Activity Against Metastatic Castration-resistant Prostate Cancer Previously Treated with Docetaxel and Abiraterone: A Multicentre Analysis - European Urology Enzalutamide Antitumour Activity Against Metastatic Castration-resistant Prostate Cancer Previously Treated with Docetaxel and Abiraterone: A Multicentre Analysis - European Urology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/870b8bc0-fc65-4a64-9840-e4f0f949bbab/gr1_lrg.jpg)
Enzalutamide Antitumour Activity Against Metastatic Castration-resistant Prostate Cancer Previously Treated with Docetaxel and Abiraterone: A Multicentre Analysis - European Urology
![Cost‐effectiveness of zoledronic acid and strontium‐89 as bone protecting treatments in addition to chemotherapy in patients with metastatic castrate‐refractory prostate cancer: results from the TRAPEZE trial (ISRCTN 12808747) - Andronis - 2017 - Cost‐effectiveness of zoledronic acid and strontium‐89 as bone protecting treatments in addition to chemotherapy in patients with metastatic castrate‐refractory prostate cancer: results from the TRAPEZE trial (ISRCTN 12808747) - Andronis - 2017 -](https://bjui-journals.onlinelibrary.wiley.com/cms/asset/2c7b34b1-c78f-44af-8514-b8bcec978451/bju13549-fig-0001-m.jpg)
Cost‐effectiveness of zoledronic acid and strontium‐89 as bone protecting treatments in addition to chemotherapy in patients with metastatic castrate‐refractory prostate cancer: results from the TRAPEZE trial (ISRCTN 12808747) - Andronis - 2017 -
![Oral formulation strategies to improve the bioavailability and mitigate the food effect of abiraterone acetate - ScienceDirect Oral formulation strategies to improve the bioavailability and mitigate the food effect of abiraterone acetate - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0378517320300533-gr1.jpg)
Oral formulation strategies to improve the bioavailability and mitigate the food effect of abiraterone acetate - ScienceDirect
![PDF) Updated Guidelines for Metastatic Hormone-sensitive Prostate Cancer: Abiraterone Acetate Combined with Castration Is Another Standard PDF) Updated Guidelines for Metastatic Hormone-sensitive Prostate Cancer: Abiraterone Acetate Combined with Castration Is Another Standard](https://www.researchgate.net/profile/Thomas-Lam-3/publication/320835013/figure/tbl4/AS:614121494040593@1523429382143/Life-prolonging-agents-used-at-the-castrate-resistant-stage_Q320.jpg)